Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases. Issue 5 (May 2010)
- Record Type:
- Journal Article
- Title:
- Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases. Issue 5 (May 2010)
- Main Title:
- Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases
- Authors:
- Jarm, Tomaz
Cemazar, Maja
Miklavcic, Damijan
Sersa, Gregor - Abstract:
- Solid tumors of various etiologies can be treated efficiently by electrochemotherapy (ECT), a combined use of electroporation (EP) and chemotherapeutic drugs, such as bleomycin and cisplatin. EP alone and ECT in particular, induce a profound reduction in tumor blood flow, which contributes to the antitumor effect. After EP and ECT, the time course of blood flow changes and follows the same two-phase pattern. The first rapid and short-lived vasoconstriction phase is followed by the second much longer-lived phase resulting from disrupted cytoskeletal structures and a compromised barrier function of the microvascular endothelium. In the case of ECT, however, tumor vascular endothelial cells are also affected by the chemotherapeutic drug, which leads to irrecoverable damage to tumor vessels and to a further decrease in tumor blood flow within hours after application of ECT. Tumor cells surviving the direct effects of ECT are consequently exposed to lack of oxygen and nutrients and are pushed into the secondary cascade of induced cell death. Clinically, the antitumor effectiveness of ECT has been proven extensively in the treatment of melanoma metastases, with 70––80% complete responses. The antivascular effects of ECT were also exploited for palliative treatment of bleeding melanoma metastases, with immediate cessation of bleeding and very good antitumor effectiveness. The antivascular effect of ECT is of utmost importance for translation of ECT into the treatment of deep-seatedSolid tumors of various etiologies can be treated efficiently by electrochemotherapy (ECT), a combined use of electroporation (EP) and chemotherapeutic drugs, such as bleomycin and cisplatin. EP alone and ECT in particular, induce a profound reduction in tumor blood flow, which contributes to the antitumor effect. After EP and ECT, the time course of blood flow changes and follows the same two-phase pattern. The first rapid and short-lived vasoconstriction phase is followed by the second much longer-lived phase resulting from disrupted cytoskeletal structures and a compromised barrier function of the microvascular endothelium. In the case of ECT, however, tumor vascular endothelial cells are also affected by the chemotherapeutic drug, which leads to irrecoverable damage to tumor vessels and to a further decrease in tumor blood flow within hours after application of ECT. Tumor cells surviving the direct effects of ECT are consequently exposed to lack of oxygen and nutrients and are pushed into the secondary cascade of induced cell death. Clinically, the antitumor effectiveness of ECT has been proven extensively in the treatment of melanoma metastases, with 70––80% complete responses. The antivascular effects of ECT were also exploited for palliative treatment of bleeding melanoma metastases, with immediate cessation of bleeding and very good antitumor effectiveness. The antivascular effect of ECT is of utmost importance for translation of ECT into the treatment of deep-seated tumors, especially in well vascularized organs, such as the liver, where it prevents bleeding of the treated area. … (more)
- Is Part Of:
- Expert review of anticancer therapy. Volume 10:Issue 5(2010)
- Journal:
- Expert review of anticancer therapy
- Issue:
- Volume 10:Issue 5(2010)
- Issue Display:
- Volume 10, Issue 5 (2010)
- Year:
- 2010
- Volume:
- 10
- Issue:
- 5
- Issue Sort Value:
- 2010-0010-0005-0000
- Page Start:
- 729
- Page End:
- 746
- Publication Date:
- 2010-05
- Subjects:
- antivascular effects -- bleeding metastases -- blood flow -- electrochemotherapy -- electroporation -- melanoma -- tumors -- vascular-disrupting effect -- vascular-targeted treatment
Cancer -- Treatment -- Periodicals
616.99406 - Journal URLs:
- http://informahealthcare.com ↗
http://www.future-drugs.com/loi/era ↗ - DOI:
- 10.1586/era.10.43 ↗
- Languages:
- English
- ISSNs:
- 1473-7140
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3842.002982
British Library DSC - BLDSS-3PM
British Library HMNTS - Digital store
British Library HMNTS - ELD Digital store - Ingest File:
- 15973.xml